- D-Wave Quantum (NYSE:QBTS) is transitioning from theoretical research to practical commercial applications in the rapidly evolving quantum computing sector.
- Wedbush reiterated an “Outperform” rating for D-Wave Quantum, reflecting strong commercial success, including nearly 2,000% growth in bookings.
- Analysts project a substantial 30.77% upside for D-Wave Quantum, further bolstered by significant government investment in quantum technology through the CHIPS and Science Act.
D-Wave Quantum (NYSE:QBTS) is a company that develops and sells quantum computing systems, software, and services. The quantum computing sector is shifting from theoretical research to practical industrial applications. This evolution is causing a fundamental re-evaluation of companies in the space, as highlighted by MarketBeat, as they begin to generate real commercial revenue.
On May 27, 2026, the analyst firm Wedbush reiterated its “Outperform” grade for D-Wave Quantum, as reported by TheFly. An “Outperform” grade means the analyst expects the stock to do better than the overall market average. The stock price was $27.48 when the grade was published, with the associated action being a hold.
This positive outlook reflects the company’s improving commercial success. D-Wave Quantum has experienced nearly 2,000% growth in bookings and expects to complete up to three annual system sales. This progress has helped fuel a 103.1% rally in the stock price since April 1, 2026, showing increased investor confidence in QBTS stock performance.
Analysts project a potential upside of 30.77% for D-Wave Quantum from its current price. In comparison, competitor IonQ (NYSE: IONQ) is projected to have a 9.92% upside. This suggests that even though both quantum computing stocks have risen, analysts see more near-term growth potential in D-Wave Quantum.
The entire quantum technology sector is receiving a boost from government investment. The U.S. Department of Commerce plans to provide about $2 billion in funding to nine quantum companies from the CHIPS and Science Act. This investment gives the firms a longer operational runway, which is the time they can operate before needing more money.
